Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial.

ABSTRACT:

Importance

Albumin supplementation may reduce mortality in patients with septic shock; however, data from randomized clinical trials are limited.

Objective

To assess the impact of albumin administration on outcomes in patients with septic shock.

Design, setting, and participants

This multicenter, open-label randomized clinical trial was conducted between October 21, 2019, and May 2, 2022. Patients from 23 intensive care units in Germany enrolled within 24 hours of the onset of septic shock were followed up for outcome data up to 90 days. The statistical trial report was completed and filed with the federal authorities in December 2023; additional analyses were completed in October 2024. The study was terminated prematurely due to low enrollment rates.

Interventions

SUBMITTER: Sakr Y 

PROVIDER: S-EPMC12921518 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature